NDAORALTABLETPriority Review
Approved
Mar 2017
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Lamivudine and zidovudine is a fixed-dose combination nucleoside reverse transcriptase inhibitor (NRTI) tablet for oral administration. This combination treats HIV-1 infection by inhibiting viral reverse transcriptase, reducing viral replication and slowing disease progression. The product represents a foundational antiretroviral regimen in HIV management.
Peak
Peak lifecycle stage suggests stable revenue base with established commercial infrastructure; team size likely stable to optimizing rather than expanding.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on a peak-lifecycle HIV combination agent offers experience managing a mature, globally important franchise with strong regulatory compliance and treatment guideline integration requirements. Career growth is incremental rather than transformational; emphasis is on market optimization, geographic expansion, and partner management in resource-limited regions.
Brand Manager
Worked on LAMIVUDINE AND ZIDOVUDINE at Aspen Pharmacare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.